Acticor Biotech

About the deal

Paris, France, March 09, 2023 – 8:00 am CET – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT – the «  »Company » »), a clinical-stage biotechnology company developing glenzocimab, a novel drug for the treatment of cardiovascular emergencies, in particular stroke, announces today the success of its capital increase for a total gross amount of 12.2 million euros, by issuing 1,1793,005 new shares at a price of €6.80 per share.

Following the success of the transaction, the funds raised will enable the Company to finance its operations until November 2023. The Company will use the proceeds of this capital increase to pursue its development plan towards the registration of glenzocimab for the emergency treatment of stroke, which will be achieved through:
• continued recruitment of patients in the ACTISAVE clinical trial (pivotal registration phase 2/3) rolled out in 7 European countries, the United Kingdom, Israel and the USA until the first futility analysis,
• the preparation of a new batch of glenzocimab and the pharmaceutical registration plan.